Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (444)	1/21/1999 1:06:00 AM
From: Steve Lokness	Respond to of 1073

Rick - a question on pharmacogenomics. There was a short article in Scientific American in the last issue that mentions a fellow who had cancer and had his cancer type studied/tested before his doctor decided on which method of attack to use. It would seem that this would be similar to pharmacogenomics but on an individual level. What role do you see this type of individual test being used? I mean how can pharmacogenomics have any value unless the individual (and/or in the case of the above mentioned cancer victim the specific cancer)is tested. I realize that I am confusing two things here and yet both would play into how successful any drug might work. IOW, Pharmacogenomics can tell how a drug might work on a given genetic type; but that would mean before the drug could be given the genetic makeup of the individual would need to be known. Seems like a huge potential to the company able to develop the database for this individual information that could then be crossed with disease information like that which was used on the cancer victim. Gez - heavy thoughts and not all that well written out. Appreciate any comments you care to make though. Good Investing; Steve